Unknown Analyst
Super. Well, good morning, everyone. Thank you for joining me today for this fireside chat with the CEO of Helus Pharma, Michael Halstead. Let me quickly read the Morgan Stanley research disclaimer. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Michael, thank you very much for joining us this early in the morning. And before we get into the details, perhaps you can give us a bit of background on Helus Pharma and where the company is today.
Michael Halstead
Chief Executive Officer
Sure. And thank you, [ Rebecca ]. Thank you, everyone, for joining us today. Certainly excited to talk about Helus Pharma. I’m Michael Halstead, the new CEO of Helus. I joined in early August. Helus Pharma is developing treatments for several mental health indications. We’re developing a novel serotonergic agonist. Our lead program, our first Phase III readout expected in the fourth quarter of this year, is the molecule is deuterated psilocin. It is for the — in development for the treatment of adjunctive major depressive disorder, MDD.
Very excited about that program, that indication, in particular, hopefully, we’ll get into that as we progress. Mid-stage program we have as well is our 004 program. That is deuterated DMT, the molecule, and that is for the treatment of generalized anxiety disorder, a very, very important indication there with a real unmet need. We, at the beginning of this year, completed a Phase II signal-finding study. We’ve told everyone that we’re finalizing the clinical trial design for the next study in that program this quarter, and we’ll be rolling details of that out very soon.
